Detection of seral p53 antibody in patients with breast carcinoma by immuno-polymerase chain reation / 中国基层医药

Objective To present a new seriological method for diagnosing breast carcinoma.Methods Seral anti-p53 antibody was detected with immuno-polymerase chain reation(Immuno-PCR).The expression of p53 in tissue was detected with enzymeimmu-nohistochemistry technique.Results The positive rate of anti-p53 antibody in serum of breast carcinoma was 39.5% and anti-p53 antibody was not found in non-carcinoma and normal controls.The positive rate of anti-p53 antibody was higher than that of non-carcinoma and normal controls(P

Detection of Serum Anti-p53 Antibodies and Their Significance in Patients with Colorectal Cancer / 대한진단검사의학회지

BACKGROUND: Mutations of the tumor suppressor gene p53 cause subsequent cellular accumulation of p53 gene product and a specific immunologic response. Detection of circulating antibodies against p53 protein has been evaluated for a tumor marker or prognostic factor for several cancers including those of the breast, stomach, ovary and lung. METHODS: Serum samples from 74 colorectal cancer patients were obtained preoperatively and anti-p53 antibody was measured by enzyme immunoassay (Anti-P53 ELISA II: PharmaCell, France). Carcinoembryonic antigen (CEA) and Carbohydrate antigen (CA) 19-9 were measured in parallel. Tissue p53 protein expression was examined by immunohistochemical staining. RESULTS: Anti-p53 antibodies were positive in the serum from 34% (25/74) of patients, but normal controls were all negative. Anti-p53 antibodies were significantly associated with p53 protein overexpression. CEA and CA19-9 were detected in 38% and 11%, respectively. There was no correlation among anti-p53 antibody, CEA and CA19-9. No differences were found between the anti-p53 antibody positive and negative groups in the following parameters: tumor site, histologic grades, Dukes stages, margin invasion, vessel invasion, lymph node and distant metastasis, and survival duration. CONCLUSIONS: The measurement of serum anti-p53 antibody is not suitable for preoperative markers of prognostic significance, but can be used as a simple serological marker for detection of p53 alteration. There should be more studies of the serum p53 antibody as a possible marker for postoperative monitoring in colorectal cancer.

Serum Anti-p53 Antibodies and p53 Protein Expression and Their Prognostic Relevance in Patients with Gastric Cance / 대한진단검사의학회지

BACKGROUND: Several cancer patients have developed antibodies that recognize the overexpressed p53 protein. In some tumor types, the presence of these antibodies is associated with a poor prognosis. Gastric cancer is a highly prevalent disease associated with a high mortality rate, so there is a need for improved serological markers for disease detection and disease behavior. METHODS: To evaluate the clinical relevance of anti-p53 antibodies and tissue p53 protein expression in gastric cancer, we investigated the presence of serum anti-p53 antibodies in 61 gastric cancer patients, using two enzyme-linked immuno-sorbent assay systems (Dianova p53-autoantibodies ELISA Kit, Hamburg, Germany (A); Pharma Cell Anti-p53 ELISA Kit II, Paris, France (B)), and p53 protein expression was immunohistochemically stained. RESULTS: We have detected serum anti-p53 antibodies in 9.8% (6/61), 18.0% (11/61) of gastric cancer patients before operation by using the A and B kit, respectively, but in none of 21 cancer-free individuals. The detectable expression of p53 protein in tissue was recognized in 49.2% (30/61) of gastric cancer patients, and in 100% (6/6) and 72.7% (7/11) of the patients with anti-p53 Ab by using the A and B kit. The presence of anti-p53 antibodies was significantly associated with high tumor stages, lymph node metastasis, advanced cancers, intestinal histological type, larger tumor size and infiltrating type, and short survival. The overexpression of the p53 protein was significantly associated with large sized tumors, advanced cancers, high tumor stage (III, IV), lymph node metastasis, distant metastasis, early death and high recurrence rate, and short survival. A positive rate for gastic CONCLUSIONS: We have shown that anti-p53 antibodies are closely related to p53 protein overexpression in tumor tissues and could be useful not only as a predictor of an unfavorable prognosis before operation, but also as a serological tumor marker for an increase in the detection rate of gastric cancer by a combination assay with anti-p53 antibodies, CEA and CA 19-9, although not as a screening test.

p53 Gene Mutation, Tumor p53 Protein Overexpression, and Serum Anti-p53 Antibody in Patients with Gastric Cancer

PURPOSE: The clinical implication of p53 mutation in gastric cancer is still unclear, as shown by the discordant results that continue to be reported in the literature. MATENRIALS AND METHODS: To assess p53 gene mutation, tumor p53 overexpression, and serum anti-p53 antibody, we employed a polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analysis, an immunohistochemistry using monoclonal antibody DO-7, and an enzyme-linked immunosorbent assay (ELISA), respectively. RESULTS: Of 169 surgical specimens of gastric cancer, mutation at exon 5~8 of the p53 was identified in 33 (19.5%) and was significantly correlated with lymph node metastasis. Overexpression of p53 was found in 62 specimens (36.7%) and had a significant correlation with tumor differentiation. Serum anti-p53 antibody was positive in 18 patients (10.7%). Twenty-three of the mutated tumors (69.7%) and 39 of the non-mutated tumors (28.7%) displayed immunoreactivity. Twelve of the immunopositive tumors (19.4%) and 6 of the immunonegative tumors produced anti-p53 antibody. These differences were statistically significant (P<0.001 and P=0.005, respectively). There was no significant difference in survival according to the mutation of p53. CONCLUSION: Mutation and overexpression of p53 can be easily detected by immunohistochemistry. However, standardization of the immunohistochemical staining method, as well as guidelines for interpreting the stained result, will produce concordant results and thereby improve clinical application.